Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03690895

Acronym

LCPVIH

Enrollment

Registered

2018-10-01

Start date

2015-03-15

Completion date

2016-10-01

Last updated

2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS Related Lymphoma, Central Nervous System Lymphoma

Brief summary

This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.

Interventions

OTHERRetrospective survival analysis

Kaplan-Meier model

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HIV infection * AIDS-related primary central nervous system lymphoma * treated with at least one infusion of methotrexate and combine antiretroviral therapy

Exclusion criteria

* prior non-Hodgkin lymphoma

Design outcomes

Primary

Measure	Time frame
Median duration of survival after diagnosis of lymphoma (years)	At the time of systematic files review (jan 2014) - average follow-up 7 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026